ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 332

Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)

Zohair Abbas1 and Marina N. Magrey2, 1Rheumatology, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, 2Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), body mass, Cardiovascular disease and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part attributed to traditional cardiovascular risk factors. Patients with PsA have higher body mass index (BMI) compared to patients with AS. Based on this we hypothesized that patients with PsA are at higher risk of CVD compared to patients with AS. The purpose of the study is to compare the risk of CVD in patients with PsA to patients with AS.

Methods:

Explorys is a clinical research informatics tool that uses unified medical language system ontologies to standardize, normalize and aggregate clinical data from multiple electronic heath records. The data are de-identified and presented through a secure web interface usable by researchers. At the time of this study several million patients from multiple distinct healthcare systems from year 1999 to 2012 were present in the Explorys database. Using the SNOMED hierarchy, we searched for all patients with a diagnosis of either PsA or AS using the terms “ankylosing spondylitis” and “psoriasis with arthropathy.”  This was further stratified by adding search term “anti tumor necrosis factor alpha drug”, and only patients using anti TNF therapy were included in the analysis. Using the first Body mass index (BMI) recorded; we categorized patients into one of three categories: < 25 kg/m2 (normal weight); 25 kg/m2 to < 30 kg/m2 (overweight); and ≥ 30 kg/m2 (obese). Presence of CVD was defined by the occurrence of myocardial infarction (MI), cerebrovascular disease or peripheral vascular disease (PVD). The occurrence of CV events was searched in a temporal sequence. The comparison between the 2 cohorts was made using Fishers exact test.

Results:

We identified 2360 cases of PsA and 1020 cases of AS from the database. Demographics are shown in the table 1. 52.5% patients with PsA had a BMI of more than 30 as compared to 37.8% patients with AS (p=0.0001). A total cholesterol > 200 was found in 41.9% patients with PsA compared to 36.6% with AS (p=0.11). HDL < 40 was found in 34.2% patients with PsA compared to 31% patients with AS (p=0.34).There was no significant difference between the PsA and AS cohorts in terms of prevalence of MI 2.1% vs 1.9% (p= 0.79), cerebrovascular disease 4.2% vs 2.9% (p-value 0.79) and PVD 5.9% vs 5.8% (p=0.93) respectively as shown in table 2.

Conclusion:

Despite higher BMI in patients with PsA, the prevalence of acute MI, cerebrovascular disease and PVD was similar to patients with AS. The results did not support our hypothesis that increased BMI in PsA increases the risk of CVD. Hence, other risk factors need to be further investigated.   

Table 1

 

 

AS n=1020 (%)

PsA n=2360 (%)

Age

 

 

 

 

25-50

520 (50)

850 (36)

 

50-65

350 (34)

1030 (43)

 

>65

100 (10)

380 (16)

Gender

 

 

 

 

Male

673 (66)

1133 (48)

 

Female

347 (34)

1227 (52)

Race

 

 

 

 

Caucasian

790 (77)

1900 (80)

 

African American

80 (8)

80 (3)

 

Asian

 

20 (1)

Table 2

 

 

 

AS (%)

PsA (%)

P value

BMI

 

 

 

 

 

<19.9

 

30/660* (4.5)

40/1580* (2.5)

0.016

 

20-24.9

150/660 (22.7)

230/1580 (14.5)

0.0001

 

25-29.9

230/660 (34.8)

480/1580 (30.3)

0.04

 

>30

250/660 (37.8)

830/1580 (52.5)

0.0001

Metabolic Profile

 

 

 

 

 

Total Cholesterol (>200)

110/300 (36.6)

340/810 (41.9)

0.11

 

HDL (<40)

90/290 (3)

260/760 (34.2)

0.34

 

HbA1c (>7)

50/200

190/590

0.06

Cardiovascular Disease

 

 

 

 

 

MI

20/1020(1.9)

50/2360 (2.1)

0.79

 

Cerebrovascular Disease

30/1020 (2.9)

100/2360 (4.2)

0.79

 

PVD

60/1020 (5.8)

140/2360 (5.9)

0.93


Disclosure:

Z. Abbas,
None;

M. N. Magrey,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cardiovascular-disease-among-patients-with-psoriatic-arthritis-compared-to-ankylosing-spondylitis-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology